Aptitude Medical Systems Expands Metrix® Platform
Aptitude Medical Systems, Inc. (Aptitude) has recently announced the addition of avian flu detection capabilities to its Metrix® platform. This development is backed by a significant contract modification worth up to $8.25 million from the Biomedical Advanced Research and Development Authority (BARDA), which is part of the U.S. Department of Health and Human Services. This move is set to enhance the platform’s existing features, which includes emergency use authorized COVID-19 and flu multiplex testing.
Strengthening Preparedness for Influenza Threats
The integration of H5 avian influenza detection into the Metrix® platform represents a critical improvement in the nation's preparedness against potential influenza outbreaks. This upgraded diagnostic capability enables healthcare providers to quickly differentiate between H5 avian flu strains and seasonal influenza subtypes, such as H1 and H3. By enhancing early detection and containment processes, Aptitude contributes to more robust responses to future influenza threats.
Expert Insights on the Development
Scott Ferguson, PhD, the CEO of Aptitude, emphasized the importance of this advancement. "This work accelerates Aptitude's mission to dramatically expand access to point-of-care molecular testing," he stated. He highlighted that this upgrade is not merely about expanding the test menu; it also enhances the nation's capacity to provide timely responses to emerging health threats.
Multiplex Testing Capabilities
The updated Metrix® platform will expand its multiplex testing capabilities. It will not only identify avian flu but also continue to detect Flu A, Flu B, and COVID-19, all while maintaining ease of use and a cost-effective profile. This simultaneous testing not only ensures rapid deployment in varied healthcare settings but also maximizes the existing platform's proven performance.
High Sensitivity and Rapid Results
JP Wang, PhD, CTO, President, and Executive Chairman of Aptitude, noted, "This award enables us to leverage our Metrix® platform to address the emerging threat while delivering the same high sensitivity, 20-minute assay time, and accessible form factor that can be used by anyone, anywhere." This reflects Aptitude’s commitment to setting new standards in molecular diagnostics, positioning patients and providers at the heart of a responsive healthcare solution.
Aptitude's Commitment to Molecular Diagnostics
With this contract modification, Aptitude is solidifying its reputation as a leader in accessible molecular testing solutions. The Metrix® system is designed for pandemic readiness, reliably delivering lab-accurate results in both clinical and at-home settings. This capability is expected to facilitate timely and effective public health responses to infectious disease threats.
About Aptitude: Aptitude is an innovative deep-tech healthcare company focused on transforming the landscape of infectious disease detection and treatment. Their mission involves democratizing diagnostics to provide actionable, lab-quality results swiftly and efficiently. Building on the success of its COVID/Flu test, which is the second FDA-authorized molecular test on the Metrix® platform, Aptitude continues to develop new solutions aimed at a comprehensive range of health and wellness conditions.
Frequently Asked Questions
What is the Metrix® platform?
The Metrix® platform is a molecular testing system developed by Aptitude for detecting infectious diseases, including COVID-19 and influenza strains.
How does the addition of avian flu detection benefit healthcare?
It enhances the ability of healthcare providers to rapidly differentiate avian flu strains from seasonal influenza, improving response and containment measures.
What is BARDA's role in this contract modification?
BARDA provides funding and support for developing medical countermeasures, like the enhanced Metrix® platform, to improve public health preparedness.
What are the testing capabilities of the updated Metrix® platform?
The updated system will detect H5 avian flu, Flu A, Flu B, and COVID-19, ensuring comprehensive testing in a quick and efficient manner.
How fast are the results from the Metrix® tests?
The Metrix® tests are designed to deliver results within approximately 20 minutes, offering quick diagnostics in various settings.
